Mouse TLR7 ELISA Kit (Colorimetric)
Novus Biologicals, part of Bio-Techne | Catalog # NBP2-76573
Key Product Details
Sample Type & Volume Required Per Well
Serum, plasma and other biological fluids (100 uL)
Sensitivity
0.19 ng/mL
Assay Range
0.31 - 20 ng/mL
Product Specifications
Assay Type
Sandwich-ELISA
Kit Type
ELISA Kit (Colorimetric)
Reactivity
Mouse
Specificity
This kit recognizes Mouse TLR7 in samples. No significant cross-reactivity or interference between Mouse TLR7 and analogues was observed.
Precision
Intra-Assay Precision (Precision within an assay) CV% < 5.08%
Inter-Assay Precision (Precision between assays) CV% < 4.4%
Recovery for Mouse TLR7 ELISA Kit (Colorimetric)
Recovery
84-106%
Linearity
Scientific Data Images for Mouse TLR7 ELISA Kit (Colorimetric)
ELISA: Mouse TLR7 ELISA Kit (Colorimetric) [NBP2-76573] -
ELISA: Mouse TLR7 ELISA Kit (Colorimetric) [NBP2-76573] - Standard Curve ReferenceKit Contents for Mouse TLR7 ELISA Kit (Colorimetric)
- Biotinylated Detection Ab Diluent
- Concentrated Biotinylated Detection Ab (100x)
- Concentrated HRP Conjugate (100x)
- Concentrated Wash Buffer (25x)
- HRP Conjugate Diluent
- Micro ELISA Plate (Dismountable)
- Plate Sealer
- Product Manual
- Reference Standard
- Sample Diluent
- Stop Solution
- Substrate Reagent
Preparation and Storage
Shipping
The product is shipped with polar packs. Upon receipt, store it immediately at the temperature recommended below.
Stability & Storage
Storage of components varies. See protocol for specific instructions.
Background: TLR7
While TLRs play an important role in innate immune response, dysfunction in the TLR-MyD88 signaling cascade has also been reported in various autoimmune disorders (5,6). Elevated expression of TLR7 is associated with increased risk of system lupus erythematosus (SLE), an autoimmune disease involving B cell hyperactivity (6,7). Studies involving mouse models has also found that increased TLR7 expression predisposes mice to a lupus-like disease (7). Therapeutics targeting TLR7 have been developed to either enhance or inhibit its activity depending on the circumstance. For example, TLR7 agonists such as imiquimod, resiquimod, and 852A are used to increase TLR7 activity for treatment of cancers and to fight viral infections (7,8). On the other hand, TLR7 antagonists inhibit its activation and have been developed to combat chronic immune stimulation as seen in inflammatory and autoimmune diseases (8).
References
1. Petes C, Odoardi N, Gee K. The Toll for Trafficking: Toll-Like Receptor 7 Delivery to the Endosome. Front Immunol. 2017;8:1075. https://doi.org/10.3389/fimmu.2017.01075
2. Maeda K, Akira S. TLR7 Structure: Cut in Z-Loop. Immunity. 2016;45(4):705-707. https://doi.org/10.1016/j.immuni.2016.10.003
3. Krieg AM, Vollmer J. Toll-like receptors 7, 8, and 9: linking innate immunity to autoimmunity. Immunol Rev. 2007;220:251-269. https://doi.org/10.1111/j.1600-065X.2007.00572.x
4. Uniprot (Q9NYK1)
5. Zheng C, Chen J, Chu F, Zhu J, Jin T. Inflammatory Role of TLR-MyD88 Signaling in Multiple Sclerosis. Front Mol Neurosci. 2020;12:314. https://doi.org/10.3389/fnmol.2019.00314
6. Chi H, Li C, Zhao FS, et al. Anti-tumor Activity of Toll-Like Receptor 7 Agonists. Front Pharmacol. 2017;8:304. https://doi.org/10.3389/fphar.2017.00304
7. Fillatreau S, Manfroi B, Dorner T. Toll-like receptor signalling in B cells during systemic lupus erythematosus. Nat Rev Rheumatol. 2021;17(2):98-108. https://doi.org/10.1038/s41584-020-00544-4
8. Patinote C, Karroum NB, Moarbess G, et al. Agonist and antagonist ligands of toll-like receptors 7 and 8: Ingenious tools for therapeutic purposes. Eur J Med Chem. 2020;193:112238. https://doi.org/10.1016/j.ejmech.2020.112238
Long Name
Toll-like Receptor 7
Alternate Names
toll-like receptor 7
Gene Symbol
TLR7
Additional TLR7 Products
Product Documents for Mouse TLR7 ELISA Kit (Colorimetric)
Product Specific Notices for Mouse TLR7 ELISA Kit (Colorimetric)
This product is for research use only and is not approved for use in humans or in clinical diagnosis. ELISA Kits are guaranteed for 6 months from date of receipt.
Loading...
Loading...
Loading...
Loading...